A New Guideline for Safer Immunosuppression: Updating Thiopurine Dosing in the Genomic Era
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has released its 2025 update for dosing thiopurine drugs like azathioprine, mercaptopurine, and thioguanine. These immunosuppressants, used in conditions from leukemia to autoimmune diseases, carry a significant risk of severe myelosuppression. The guideline provides refined, evidence-based recommendations for adjusting starting doses based on a patient’s genetic profile, specifically focusing on variants in the TPMT and NUDT15 genes, which are critical for drug metabolism. This update underscores the importance of preemptive pharmacogenetic testing to personalize therapy and mitigate life-threatening adverse drug reactions across diverse patient populations.
Why it might matter to you: For critical care professionals managing patients with drug-induced pancytopenia or multi-organ failure following immunosuppression, this guideline is a vital risk-mitigation tool. It directly informs safer medication initiation in vulnerable populations, potentially preventing admissions for sepsis or shock secondary to myelosuppression. Implementing this pharmacogenetic strategy aligns with precision medicine goals in the ICU, where optimizing drug efficacy while minimizing iatrogenic harm is paramount.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.